Image IQ Quiz: What Does the PET/CT Image Reveal?

The use of ivonescimab was correlated with a median 5.3-month improvement in progression-free survival (PFS) over pembrolizumab in patients with PD-L1 positive non-small cell lung cancer, according to CT and MRI findings from a phase 3 randomized multicenter trial.

Drs. Charles Liu and Jonathan Russin discuss the benefits and potential of fPACT, the alternative to functional MRI.

Ultra-high spatial resolution with photon-counting CT facilitated a 33 percent reduction in the assessment of median total plaque volume and a 45 percent higher inter-reader agreement for evaluation of low-attenuation plaque volume in contrast to energy-integrating detector (EID) CT.

In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.

In patients who had at least four cycles of 177Lu-PSMA-I&T for mCRPC, new research shows that a 10 percent or greater decrease in total kidney volume on CT at six months has a 90 percent AUC for predicting estimated glomerular filtration rates (eGFRs) of 30 percent or greater at one year.

For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.